Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

• Michail Ignatiadis ,

  Contributed equally to this work with: Michail Ignatiadis, Dimitrios Zardavas

  * E-mail: michail.ignatiadis@bordet.be

  Affiliations Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Dimitrios Zardavas ,

  Contributed equally to this work with: Michail Ignatiadis, Dimitrios Zardavas

  Affiliation Breast International Group (BIG aisbl), Brussels, Belgium

  ⨯
• Marc Lemort,

  Affiliation Department of Radiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Celine Wilke,

  Affiliation Medigene AG, Planegg, Germany

  ⨯
• Marie-Catherine Vanderbeeken,

  Affiliation Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Veronique D’Hondt,

  Affiliation Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Evandro De Azambuja,

  Affiliation Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Andrea Gombos,

  Affiliation Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Fabienne Lebrun,

  Affiliation Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Lissandra Dal Lago,

  Affiliation Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Fanny Bustin,

  Affiliation Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Marion Maetens,

  Affiliation Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Lieveke Ameye,

  Affiliation Department of Biostatistics, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Isabelle Veys,

  Affiliation Department of Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Stefan Michiels,

  Affiliation Service de Biostatistique et d’Epidémiologie, Gustave Roussy, Univ. Paris-Sud, Villejuif, France

  ⨯
• Marianne Paesmans,

  Affiliation Department of Radiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Denis Larsimont,

  Affiliation Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Christos Sotiriou,

  Affiliations Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Jean-Marie Nogaret,

  Affiliation Department of Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• Martine Piccart,

  Affiliations Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium, Breast International Group (BIG aisbl), Brussels, Belgium

  ⨯
•  [ ... ],
• Ahmad Awada

  Affiliation Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

  ⨯
• [ view all ]
• [ view less ]